38
Participants
Start Date
March 31, 2007
Primary Completion Date
May 31, 2010
Study Completion Date
May 31, 2010
Gemcitabine, Carboplatin, Bevacizumab
Patients will be treated with Gemcitabine 2000mg/m\^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
Hubert H. Humphrey Cancer Center, Minneapolis
University of Minnesota Cancer Center, Minneapolis
Collaborators (1)
Eli Lilly and Company
INDUSTRY
Genentech, Inc.
INDUSTRY
Masonic Cancer Center, University of Minnesota
OTHER